Key result
Combination therapy with beta-blockers and ACE inhibitors in chronic heart failure patients was associated with lower Th1 to Th2 cytokine ratios (p=0.0373).
Why the study?
Does beta-blocker and ACE inhibitor therapy reduce inflammatory cytokine production in patients with chronic heart failure?
Cross-Sectional (n=118)
No
Does beta-blocker and ACE inhibitor therapy reduce inflammatory cytokine production in patients with chronic heart failure?
Beta-blocker and ACE inhibitor therapy in chronic heart failure is associated with a potentially beneficial reduction in inflammatory cytokine production and sympathetic tone.
Associated cytokine shift with combination therapy is hypothesis-generating in HF; does not support practice change.
OBJECTIVE: To examine the potential impact of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors, medications which modulate beta-adrenergic signaling, on immune function in patients with chronic heart failure (HF). METHODS: 118 patients attending an HF center were tested for circulating levels of norepinephrine (NE), T cells and the inflammation-associated cytokine interleukin 6 (IL-6). Levels of the cytokines interferon-gamma (IFNgamma), IL-10, and tumor necrosis factor-alpha (TNFalpha) produced by cultured peripheral blood mononuclear cells (PBMC) were measured in culture supernatants following T cell stimulation in vitro. RESULTS: NE levels were significantly lower in patients receiving ACE inhibitors (p = 0.0263), with a trend toward lower NE in patients receiving beta-blockers. All patients exhibited relatively normal levels of T cells, and there was a trend toward higher levels of total (CD3+) and helper (CD4+) T cells (p = 0.0578 and 0.0932, respectively) in patients receiving either type of medication. The ratios of Th1 (IFNgamma) to Th2 (IL-10) cytokines were lower in patients receiving a combination of beta-blocker and ACE inhibitor therapy (p = 0.0373). NYHA class was a significant predictor of serum IL-6 (p < 0.0001). There was a trend toward lower levels of serum IL-6 in patients receiving both types of medications (p = 0.0606). TNFalpha production by CD3/CD28-stimulated PBMC was significantly lower in patients receiving ACE inhibitor medications (p = 0.0223). CONCLUSIONS: These results suggest that high sympathetic tone associated with chronic HF affects Th1/Th2 and inflammatory cytokine production, and that these effects can be modulated by medications. In addition to improvement in clinical parameters relating to cardiovascular function, beta-blocker and ACE inhibitor medications also appear to have a beneficial effect on the immune system in HF.
No takes yet. Share an insight, caveat, or question.
Gage et al. (2004) conducted a cross-sectional in Chronic heart failure (n=118). Beta-blockers and ACE inhibitors was evaluated on Th1 (IFNgamma) to Th2 (IL-10) cytokine ratios (p=0.0373). Combination therapy with beta-blockers and ACE inhibitors in chronic heart failure patients was associated with lower Th1 to Th2 cytokine ratios (p=0.0373).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: